Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

WATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the appointment of Michaela Levin, Ph.D., as chief business officer, effective August 31, 2026. Dr. Levin comes with a solid, broad background in biotechnology business development, corporate strategy and transactional execution spanning mergers and acquisitions, global and regional partnerships, technology licensing and strategic portfolio development. In her role at Acrivon, she will work in close concert with the executive team leading the company’s business development and partnering activities, including the identification, evaluation and execution of strategic opportunities designed to maximize the value of Acrivon’s AP3 platform and pipeline.